Literature DB >> 29071521

CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase.

Sainan Cheng1, Yeon Hyeon Choe2, Hideki Ota3, Chen Cui1, Gang Yin1, Minjie Lu1, Lu Li1, Xiuyu Chen1, Sanjay K Prasad4, Shihua Zhao5.   

Abstract

End-stage phase of hypertrophic cardiomyopathy (ES-HCM) is a recognized part of HCM disease spectrum. Information on cardiac magnetic resonance (CMR) studies for ES-HCM especially for those without ventricular remodeling has been limited. We aimed to evaluate the morpho-functional and tissue features of ES-HCM with or without ventricular remodeling and to explore CMR prognostic value in these patients. We analysed CMR scans of sixty-three ES-HCM patients and divided them into those with ventricular dilatation (D-ES, n = 41) and those with normal ventricular size (N-ES, n = 22). Cox proportional hazards models were used to assess the association between CMR parameters and outcomes. Patients in D-ES showed hypokinetic-dilated HCM phenotype, while patients in N-ES showed hypokinetic-restrictive HCM phenotype. LGE extent was significantly larger in D-ES (34.7% ± 15.4% vs. 22.8% ± 7.7%; P < 0.01). Atrial fibrillation and edema of lower extremity were more common in N-ES (72.7 vs. 29.3% and 54.5 vs. 24.4%, respectively; P < 0.05). Log-rank test found no significant difference between 2 groups in combined end point of cardiovascular events (χ2 = 0.66, P = 0.418). In multivariate analysis, LGE (HR 1.57-1.83 per 10% LGE increase, P < 0.01) and indexed left atrial volume (LAVI) (HR 1.14-1.21 per 20 mL/m2 increase, P < 0.05) remained independently associated with combined end point when adjusted by other risk factors. The CMR features of HCM in end-stage span between two extremes. LGE is more extensive in those with ventricular remodeling and LAVI is larger in those with normal ventricular size. Both LGE and LAVI are significant predictors of poor outcomes.

Entities:  

Keywords:  CMR; HCM; Heat failure; Late gadolinium enhancement

Mesh:

Substances:

Year:  2017        PMID: 29071521     DOI: 10.1007/s10554-017-1263-3

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  34 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison with those of dilated cardiomyopathy.

Authors:  Tomoyuki Hamada; Toru Kubo; Hiroaki Kitaoka; Takayoshi Hirota; Eri Hoshikawa; Kayo Hayato; Yuji Shimizu; Makoto Okawa; Naohito Yamasaki; Yoshihisa Matsumura; Toshikazu Yabe; Jun Takata; Yoshinori L Doi
Journal:  Clin Cardiol       Date:  2010-07       Impact factor: 2.882

3.  Risk of sudden death in end-stage hypertrophic cardiomyopathy.

Authors:  Hirotaka Kawarai; Katsuya Kajimoto; Yuichiro Minami; Nobuhisa Hagiwara; Hiroshi Kasanuki
Journal:  J Card Fail       Date:  2011-03-25       Impact factor: 5.712

Review 4.  Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.

Authors:  Zhen Weng; Jialu Yao; Raymond H Chan; Jun He; Xiangjun Yang; Yafeng Zhou; Yang He
Journal:  JACC Cardiovasc Imaging       Date:  2016-07-20

5.  LGE Means Better Selection of HCM Patients for Primary Prevention Implantable Defibrillators.

Authors:  Barry J Maron; Martin S Maron
Journal:  JACC Cardiovasc Imaging       Date:  2016-07-20

6.  Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy.

Authors:  R Thaman; J R Gimeno; R T Murphy; T Kubo; B Sachdev; J Mogensen; P M Elliott; W J McKenna
Journal:  Heart       Date:  2005-07       Impact factor: 5.994

7.  Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Raymond H Chan; Barry J Maron; Iacopo Olivotto; Michael J Pencina; Gabriele Egidy Assenza; Tammy Haas; John R Lesser; Christiane Gruner; Andrew M Crean; Harry Rakowski; James E Udelson; Ethan Rowin; Massimo Lombardi; Franco Cecchi; Benedetta Tomberli; Paolo Spirito; Francesco Formisano; Elena Biagini; Claudio Rapezzi; Carlo Nicola De Cecco; Camillo Autore; E Francis Cook; Susie N Hong; C Michael Gibson; Warren J Manning; Evan Appelbaum; Martin S Maron
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

8.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Iacopo Olivotto; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Paolo G Camici
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

9.  Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy: A Clinical-Pathological Study of 30 Explanted Hearts.

Authors:  Giuseppe Galati; Ornella Leone; Ferdinando Pasquale; Iacopo Olivotto; Elena Biagini; Francesco Grigioni; Emanuele Pilato; Massimiliano Lorenzini; Barbara Corti; Alberto Foà; Valentina Agostini; Franco Cecchi; Claudio Rapezzi
Journal:  Circ Heart Fail       Date:  2016-09       Impact factor: 8.790

10.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors:  Perry Elliott; Bert Andersson; Eloisa Arbustini; Zofia Bilinska; Franco Cecchi; Philippe Charron; Olivier Dubourg; Uwe Kühl; Bernhard Maisch; William J McKenna; Lorenzo Monserrat; Sabine Pankuweit; Claudio Rapezzi; Petar Seferovic; Luigi Tavazzi; Andre Keren
Journal:  Eur Heart J       Date:  2007-10-04       Impact factor: 29.983

View more
  5 in total

Review 1.  Tissue-level inflammation and ventricular remodeling in hypertrophic cardiomyopathy.

Authors:  Richard C Becker; A Phillip Owens; Sakthivel Sadayappan
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

2.  Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis.

Authors:  Yishay Wasserstrum; José M Larrañaga-Moreira; Cristina Martinez-Veira; Edward Itelman; Dor Lotan; Avi Sabbag; Rafael Kuperstein; Yael Peled; Dov Freimark; Roberto Barriales-Villa; Michael Arad
Journal:  ESC Heart Fail       Date:  2022-04-30

Review 3.  Cardiac magnetic resonance imaging in the evaluation of patients with hypertrophic cardiomyopathy.

Authors:  Juan Carlos Brenes; Adelina Doltra; Susanna Prat
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12

4.  T2-weighted cardiac magnetic resonance image and myocardial biomarker in hypertrophic cardiomyopathy.

Authors:  Shi Chen; Liwei Huang; Qing Zhang; Jie Wang; Yucheng Chen
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

Review 5.  Cardiac magnetic resonance in the assessment of hypertrophic cardiomyopathy phenotypes and stages - pictorial review.

Authors:  Magdalena Stachera; Paweł Przybyło; Katarzyna Sznajder; Marek Gierlotka
Journal:  Pol J Radiol       Date:  2021-12-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.